Webinar: Avoid unnecessary delays getting cell therapies to market


Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market.

Learn about important considerations when sourcing Leukocytes/Cellular starting materials and related ancillary products that must be factored into your programme to efficiently move through the clinical pipeline and successfully receive regulatory approval.

In this webinar from BioIVT, the panel of experts discuss important topics including:

  • Why is it so important to have a dedicated supplier with recallable donors that is compliant with GTPs and GMPs?
  • Can a manufacturer of a cell or gene therapy switch suppliers midstream in clinical development?
  • What are the costs and time delays of switching suppliers later in clinical development?
  • How will not having a GMP supplier impact the speed a therapy gets to market?

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free